Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review

References

• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134. doi: 10.1056/NEJMoa060655
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124. doi: 10.1056/NEJMoa065044
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–1068. doi: 10.1200/JCO.2009.23.9764
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–1939. doi: 10.1016/S0140-6736(11)61613-9
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–2111. doi: 10.1016/S0140-6736(07)61904-7
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–5428. doi: 10.1200/JCO.2008.16.9847
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–1823. doi: 10.1056/NEJMoa1510016
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482. doi: 10.1016/S1470-2045(15)00290-9
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281. doi: 10.1056/NEJMoa066838
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–456. doi: 10.1016/S0140-6736(08)61039-9
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ, Longo DL. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–366. doi:10.1056/NEJMra1601333
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi: 10.1056/NEJMoa1712126
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799. doi: 10.1200/JCO.2008.21.4809
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–148. doi: 10.1016/S1470-2045(12)70559-4
   PubMed Web of Science ®Google Scholar
• Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128(11):2085–2097. doi: 10.1002/cncr.34180
   PubMed Web of Science ®Google Scholar
• Tannir NM, Escudier B, Df M, et al. Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial. J Clin Oncol. 2024;42(4_suppl):363–363. doi: 10.1200/JCO.2024.42.4_suppl.363
   Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi: 10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi: 10.1056/NEJMoa1816047
   PubMed Web of Science ®Google Scholar
• Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–2415. doi: 10.1016/S0140-6736(19)30723-8
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. doi: 10.1056/NEJMoa2026982
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. doi: 10.1056/NEJMoa2035716
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888–898. doi: 10.1016/S1470-2045(22)00290-X
   PubMed Web of Science ®Google Scholar
• Bourlon MT, Escudier B, Burotto M, et al. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): results from 55-month follow-up of the CheckMate 9ER trial. J Clin Oncol. 2024;42(4_suppl):362–362. doi: 10.1200/JCO.2024.42.4_suppl.362
   Google Scholar
• Motzer RJ, Porta C, Eto M, et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol. 2024;42(11):1222–1228. doi: 10.1200/JCO.23.01569
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24(3):228–238. doi: 10.1016/S1470-2045(23)00049-9
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030–1039. doi: 10.1016/j.annonc.2020.04.010
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Powles T, Atkins MB, et al. Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 2022;8(2):275–280. doi: 10.1001/jamaoncol.2021.5981
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Albiges L, et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med. 2023;388(19):1767–1778. doi: 10.1056/NEJMoa2212851
   PubMed Web of Science ®Google Scholar
• Powles T, Motzer RJ, Albiges L, et al. Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk. J Clin Oncol. 2023;41(6_suppl):605–605. doi: 10.1200/JCO.2023.41.6_suppl.605
   Google Scholar
• Haanen J, Ernstoff MS, Wang Y, et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol. 2020;31(6):724–744. doi: 10.1016/j.annonc.2020.03.285
   PubMed Web of Science ®Google Scholar
• Rini BI, Battle D, Figlin RA, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019;7(1):354. doi: 10.1186/s40425-019-0813-8
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591–597. doi: 10.1200/JCO.2016.70.7398
   PubMed Web of Science ®Google Scholar
• Hirsch L, Martinez Chanza N, Farah S, et al. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. JAMA Oncol. 2021;7(12):1815–1823. doi: 10.1001/jamaoncol.2021.4544
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82(4):399–410. doi: 10.1016/j.eururo.2022.03.006
   PubMed Web of Science ®Google Scholar
• Auvray M, Auclin E, Barthelemy P, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer. 2019;108:33–40. doi: 10.1016/j.ejca.2018.11.031
   PubMed Web of Science ®Google Scholar
• Lemelin A, Takemura K, Boyne DJ, et al. 1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): a target trial emulation using real-world data from the international mRCC database consortium (IMDC). Annals Oncology. 2023;34:S1023–S1024.
   Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–1659. doi: 10.1056/NEJMoa003013
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–970. doi: 10.1016/S0140-6736(01)06103-7
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–1076. doi:10.1097/01.ju.0000110610.61545.ae
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–66. doi: 10.1016/j.juro.2010.09.012
   PubMed Web of Science ®Google Scholar
• Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur Urol. 2014;66(4):704–710. doi: 10.1016/j.eururo.2014.05.034
   PubMed Web of Science ®Google Scholar
• Hanna N, Sun M, Meyer CP, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J Clin Oncol. 2016;34(27):3267–3275. doi: 10.1200/JCO.2016.66.7931
   PubMed Web of Science ®Google Scholar
• Mejean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–427. doi: 10.1056/NEJMoa1803675
   PubMed Web of Science ®Google Scholar
• Mejean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol. 2021;80(4):417–424. doi: 10.1016/j.eururo.2021.06.009
   PubMed Web of Science ®Google Scholar
• Arora S, Sood A, Dalela D, et al. Cytoreductive nephrectomy: assessing the generalizability of the CARMENA Trial to Real-world national cancer data base cases. Eur Urol. 2019;75(2):352–353. doi: 10.1016/j.eururo.2018.10.054
   PubMed Web of Science ®Google Scholar
• Studentova H, Rusarova N, Ondruskova A, et al. The role of cytoreductive nephrectomy in renal cell carcinoma with sarcomatoid histology: a case series and review of the literature. Curr Oncol. 2022;29(8):5475–5488. doi: 10.3390/curroncol29080433
   PubMed Web of Science ®Google Scholar
• Mejean A, Thezenas S, Chevreau C, et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): update on Carmena trial with focus on intermediate IMDC-risk population. J Clin Oncol. 2019;37(15_suppl):4508–4508. doi: 10.1200/JCO.2019.37.15_suppl.4508
   Web of Science ®Google Scholar
• Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the surtime randomized clinical trial. JAMA Oncol. 2019;5(2):164–170. doi: 10.1001/jamaoncol.2018.5543
   PubMed Web of Science ®Google Scholar
• Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the national cancer database. Urol Oncol. 2020;38(6):.e604.9–.e604.17. doi: 10.1016/j.urolonc.2020.02.029
   Web of Science ®Google Scholar
• Bakouny Z, El Zarif T, Dudani S, et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium. Eur Urol. 2023;83(2):145–151. doi: 10.1016/j.eururo.2022.10.004
   PubMed Web of Science ®Google Scholar
• Takemura K, Ernst MS, Navani V, et al. Characterization of patients with metastatic renal cell carcinoma undergoing deferred, upfront, or No cytoreductive nephrectomy in the era of combination immunotherapy: results from the international metastatic renal cell carcinoma database consortium. Eur Urol Oncol. 2024;7(3):501–508. doi: 10.1016/j.euo.2023.10.002
   PubMed Web of Science ®Google Scholar
• Abel EJ, Master VA, Spiess PE, et al. The selection for cytoreductive nephrectomy (SCREEN) score: improving surgical risk stratification by integrating common radiographic features. Eur Urol Oncol. 2024;7(2):266–274. doi: 10.1016/j.euo.2023.06.008
   PubMed Web of Science ®Google Scholar
• Pignot G, Thiery-Vuillemin A, Walz J, et al. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge? Eur Urol. 2020;77(6):761–763. doi: 10.1016/j.eururo.2019.12.018
   PubMed Web of Science ®Google Scholar
• Meza L, Chawla NS, Giannarini G, et al. Cytoreductive Nephrectomy in 2021: Obsolete. Eur Urol Open Sci. 2022;36:44–46. doi: 10.1016/j.euros.2021.09.021
   PubMedGoogle Scholar
• Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the Targeted Therapy Era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol. 2019;75(1):111–128. doi: 10.1016/j.eururo.2018.09.016
   PubMed Web of Science ®Google Scholar
• Boni A, Cochetti G, Ascani S, et al. Robotic treatment of oligometastatic kidney tumor with synchronous pancreatic metastasis: case report and review of the literature. BMC Surg. 2018;18(1):40. doi: 10.1186/s12893-018-0371-x
   PubMed Web of Science ®Google Scholar
• Ishihara H, Takagi T, Kondo T, et al. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. Urol Oncol. 2021;39(1):e77 17–e77 25. doi: 10.1016/j.urolonc.2020.08.011
   Web of Science ®Google Scholar
• Stuhler V, Herrmann L, Maas M, et al. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies. World J Urol. 2022;40(5):1175–1183. doi: 10.1007/s00345-022-03960-1
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683–694. doi: 10.1056/NEJMoa2106391
   PubMed Web of Science ®Google Scholar
• Wu K, Liu Z, Shao Y, et al. Nomogram predicting survival to assist decision-making of metastasectomy in patients with metastatic renal cell carcinoma. Front Oncol. 2020;10:592243. doi:10.3389/fonc.2020.592243
   PubMed Web of Science ®Google Scholar
• Ruatta F, Derosa L, Escudier B, et al. Prognosis of renal cell carcinoma with bone metastases: experience from a large cancer centre. Eur J Cancer. 2019;107:79–85. doi: 10.1016/j.ejca.2018.10.023
   PubMed Web of Science ®Google Scholar
• Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer. 2011;117(3):501–509. doi: 10.1002/cncr.25452
   PubMed Web of Science ®Google Scholar
• Pierrard J, Tison T, Grisay G, et al. Global management of brain metastasis from renal cell carcinoma. Crit Rev Oncol Hematol. 2022;171:103600. doi:10.1016/j.critrevonc.2022.103600
   PubMed Web of Science ®Google Scholar
• Chevreau C, Ravaud A, Escudier B, et al. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer. 2014;12(1):50–54. doi: 10.1016/j.clgc.2013.09.008
   PubMed Web of Science ®Google Scholar
• Brown LC, Desai K, Wei W, et al. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. J Immunother Cancer. 2021;9(9):e003281. doi: 10.1136/jitc-2021-003281
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655–663. doi: 10.1016/S1470-2045(20)30111-X
   PubMed Web of Science ®Google Scholar
• Takemura K, Lemelin A, Ernst MS, et al. Outcomes of patients with brain metastases from renal cell carcinoma receiving first-line therapies: results from the international metastatic renal cell carcinoma database consortium. Eur Urol. Forthcoming. doi: 10.1016/j.eururo.2024.01.006
   Google Scholar
• Siva S, Kothari G, Muacevic A, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol. 2017;14(9):549–563. doi: 10.1038/nrurol.2017.87
   PubMed Web of Science ®Google Scholar
• Correa RJM, Louie AV, Zaorsky NG, et al. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and Meta-analysis. Eur Urol Focus. 2019;5(6):958–969. doi: 10.1016/j.euf.2019.06.002
   PubMedGoogle Scholar
• Zaorsky NG, Lehrer EJ, Kothari G, et al. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019;2(5):515–523. doi:10.1016/j.euo.2019.05.007
   PubMed Web of Science ®Google Scholar
• Stenman M, Sinclair G, Paavola P, et al. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. Radiother Oncol. 2018;127(3):501–506. doi: 10.1016/j.radonc.2018.04.028
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(1):71–90. doi: 10.6004/jnccn.2022.0001
   PubMedGoogle Scholar
• Lalani A-K, Swaminath A, Pond GR, et al. Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). J Clin Oncol. 2022;40(6_suppl):TPS398–TPS398. doi: 10.1200/JCO.2022.40.6_suppl.TPS398
   Web of Science ®Google Scholar
• Zhang Y, Schoenhals J, Christie A, et al. Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys. 2019;105(2):367–375. doi: 10.1016/j.ijrobp.2019.07.023
   PubMed Web of Science ®Google Scholar
• Tang C, Msaouel P, Hara K, et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021;22(12):1732–1739. doi: 10.1016/S1470-2045(21)00528-3
   PubMed Web of Science ®Google Scholar
• Hannan R, Christensen M, Christie A, et al. Stereotactic ablative radiation for systemic therapy–naïve oligometastatic kidney cancer. Eur Urol Oncol. 2022;5(6):695–703. doi: 10.1016/j.euo.2022.06.008
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–382. doi:10.1038/nrclinonc.2011.44
   PubMed Web of Science ®Google Scholar
• Hannan R, Christensen M, Hammers H, et al. Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer. Eur Urol Oncol. 2022;5(2):216–224. doi: 10.1016/j.euo.2021.12.001
   PubMed Web of Science ®Google Scholar
• Cheung P, Patel S, North SA, et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur Urol. 2021;80(6):693–700. doi: 10.1016/j.eururo.2021.07.026
   PubMed Web of Science ®Google Scholar
• Liu Y, Dong Y, Kong L, et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):104. doi:10.1186/s13045-018-0647-8
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Z, Liu R, et al. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma. Radiat Oncol. 2021;16(1):211. doi: 10.1186/s13014-021-01937-9
   PubMed Web of Science ®Google Scholar
• Hammers HJ, Vonmerveldt D, Ahn C, et al. Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). J Clin Oncol. 2020;38(6_suppl):614–614. doi: 10.1200/JCO.2020.38.6_suppl.614
   Web of Science ®Google Scholar
• Masini C, Iotti C, De Giorgi U, et al. Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study. Eur Urol. 2022;81(3):274–282. doi: 10.1016/j.eururo.2021.09.016
   PubMed Web of Science ®Google Scholar
• Gu CY, Wang JJ, Zhang HL, et al. Survival in metastatic renal cell carcinoma patients treated with sunitinib with or without cryoablation. Front Oncol. 2021;11:762547. doi:10.3389/fonc.2021.762547
   PubMedGoogle Scholar
• Liu C, Cao F, Xing W, et al. Efficacy of cryoablation combined with sorafenib for the treatment of advanced renal cell carcinoma. Int J Hyperthermia. 2019;36(1):220–228. doi: 10.1080/02656736.2018.1556819
   PubMed Web of Science ®Google Scholar
• Tsimafeyeu I, Zart JS, Chung B. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α. BJU Int. 2013;112(1):32–38. doi: 10.1111/bju.12107
   PubMed Web of Science ®Google Scholar
• Maciolek KA, Abel EJ, Best SL, et al. Percutaneous microwave ablation for local control of metastatic renal cell carcinoma. Abdom Radiol (NY). 2018;43(9):2446–2454. doi: 10.1007/s00261-018-1498-z
   PubMed Web of Science ®Google Scholar
• Bang HJ, Littrup PJ, Goodrich DJ, et al. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J Vasc Interv Radiol. 2012;23(6):770–777. doi: 10.1016/j.jvir.2012.03.002
   PubMed Web of Science ®Google Scholar
• Gardner CS, Ensor JE, Ahrar K, et al. Cryoablation of bone metastases from renal cell carcinoma for local tumor control. J Bone Joint Surg Am. 2017;99(22):1916–1926. doi: 10.2106/JBJS.16.01182
   PubMed Web of Science ®Google Scholar
• Matin SF, Sharma P, Gill IS, et al. Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol. 2010;183(1):333–338. doi: 10.1016/j.juro.2009.08.110
   PubMed Web of Science ®Google Scholar
• Campbell MT, Matin SF, Tam AL, et al. Pilot study of tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021;12(1):6375. doi: 10.1038/s41467-021-26415-4
   PubMed Web of Science ®Google Scholar
• Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2021;27(1):78–86. doi: 10.1158/1078-0432.CCR-20-2063
   PubMed Web of Science ®Google Scholar
• Rini BI, Brugarolas J, Atkins MB. Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma. J Immunother Cancer. 2023;11(3):e006361. doi: 10.1136/jitc-2022-006361
   PubMed Web of Science ®Google Scholar
• Albiges L, Flippot R, Rioux-Leclercq N, et al. Non–clear cell renal cell carcinomas: from shadow to light. J Clin Oncol. 2018;36(36):3624–3631. doi: 10.1200/JCO.2018.79.2531
   Web of Science ®Google Scholar
• Tykodi SS, Gordan LN, Alter RS, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer. 2022;10(2):e003844. doi: 10.1136/jitc-2021-003844
   PubMed Web of Science ®Google Scholar
• Lee CH, Voss MH, Carlo MI, et al. Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol. 2022;40(21):2333–2341. doi: 10.1200/JCO.21.01944
   PubMed Web of Science ®Google Scholar
• Albiges L, Gurney H, Atduev V, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023;24(8):881–891. doi: 10.1016/S1470-2045(23)00276-0
   PubMed Web of Science ®Google Scholar
• Graham J, Wells JC, Dudani S, et al. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. Eur J Cancer. 2022;171:124–132. doi: 10.1016/j.ejca.2022.05.002
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Banchereau R, Hamidi H, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38(6):803–817.e4. doi: 10.1016/j.ccell.2020.10.011
   PubMed Web of Science ®Google Scholar
• Vano YA, Elaidi R, Bennamoun M, et al. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):612–624. doi: 10.1016/S1470-2045(22)00128-0
   PubMed Web of Science ®Google Scholar